Chen Dengyue, Singh Dhananjay, Sirkar Kamalesh K, Pfeffer Robert
Otto York Department of Chemical, Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, University Heights , Newark, New Jersey 07102, United States.
Langmuir. 2015;31(1):432-41. doi: 10.1021/la503179t. Epub 2014 Dec 31.
Using porous hollow fiber membranes, this study illustrates a novel technique to continuously synthesize polymer-coated drug crystals by antisolvent crystallization. The synthesized polymer-coated drug crystals involve crystals of the drug Griseofulvin (GF) coated by a thin layer of the polymer Eudragit RL100. The process feed, an acetone solution of the drug GF containing the dissolved polymer, was passed through the shell side of a membrane module containing many porous hollow fibers of Nylon-6. Through the lumen of the hollow fibers, the antisolvent water was passed at a higher pressure to inject water jets through every pore in the fiber wall into the shell-side acetone feed solution, creating an extremely high level of supersaturation and immediate crystallization. It appears that the GF crystals are formed first and serve as nuclei for the precipitation of the polymer Eudragit, which forms a thin coating around the GF crystals. The polymer-coated drug crystals were collected by a filtration device at the shell-side outlet of the membrane module, and the surface morphology, particle size distribution, and the polymer coating thickness were then characterized by scanning electron microscopy (SEM), scanning transmission electron microscopy (STEM), laser diffraction spectroscopy (LDS), and thermogravimetric analysis (TGA). To study the properties of the coated drug crystals, X-ray diffraction (XRD), Raman spectroscopy, and dissolution tests were implemented. These results indicate that a polymer-coated, free-flowing product was successfully developed under appropriate conditions in this novel porous hollow fiber antisolvent crystallization (PHFAC) method. The coated drug particles can be potentially used for controlled release. The molecular and the crystal structures of GF were not affected by the PHFAC method, which may be easily scaled up.
本研究利用多孔中空纤维膜,阐述了一种通过抗溶剂结晶连续合成聚合物包衣药物晶体的新技术。合成的聚合物包衣药物晶体包括由聚合物Eudragit RL100薄层包衣的灰黄霉素(GF)药物晶体。工艺进料是含有溶解聚合物的药物GF的丙酮溶液,通过包含许多尼龙-6多孔中空纤维的膜组件的壳侧。通过中空纤维的内腔,以较高压力通入抗溶剂水,通过纤维壁上的每个孔将水射流注入壳侧丙酮进料溶液中,产生极高的过饱和度并立即结晶。似乎GF晶体首先形成,并作为聚合物Eudragit沉淀的核,Eudragit在GF晶体周围形成薄涂层。聚合物包衣药物晶体通过膜组件壳侧出口处的过滤装置收集,然后通过扫描电子显微镜(SEM)、扫描透射电子显微镜(STEM)、激光衍射光谱(LDS)和热重分析(TGA)对其表面形态、粒度分布和聚合物包衣厚度进行表征。为了研究包衣药物晶体的性质,进行了X射线衍射(XRD)、拉曼光谱和溶出试验。这些结果表明,在这种新型多孔中空纤维抗溶剂结晶(PHFAC)方法的适当条件下,成功开发出了一种聚合物包衣的自由流动产品。包衣药物颗粒可潜在地用于控释。GF的分子和晶体结构不受PHFAC方法的影响,该方法可能易于放大。